Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.

abstract：BACKGROUND:Adherence to treatment is a key condition in preventing relapses in inflammatory bowel disease (IBD). The aims of this study were specifically to study socioeconomic and psychological factors and adherence to treatment in a large cohort of patients. METHODS:A questionnaire concerning demographic, clinical, ...

journal_title：Inflammatory bowel diseases

authors： Nahon S,Lahmek P,Saas C,Durance C,Olympie A,Lesgourgues B,Gendre JP

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Vitamin A is an important regulator of the human immune system, especially in the gut. Recent studies have revealed that retinoic acid (RA) in gut-associated dendritic cells (DCs) enhances the transforming growth factor (TGF)-beta-dependent conversion of naïve T cells into regulatory T (Treg) cells. Thus, RA...

journal_title：Inflammatory bowel diseases

authors： Wada Y,Hisamatsu T,Kamada N,Okamoto S,Hibi T

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:Oral ferrous iron therapy may reinforce intestinal inflammation. One possible mechanism is by catalyzing the production of reactive oxygen species. We studied the effects of low-dose oral ferrous fumarate on intestinal inflammation and plasma redox status in dextran sulfate sodium (DSS)-induced colitis in ra...

journal_title：Inflammatory bowel diseases

authors： Erichsen K,Milde AM,Arslan G,Helgeland L,Gudbrandsen OA,Ulvik RJ,Berge RK,Hausken T,Berstad A

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:Mucosal expression of immunological mediators is modified in inflammatory bowel disease (IBD). Quantification of target gene messenger RNA (mRNA) transcripts depends on the normalization to a housekeeping or reference gene. Stability of housekeeping gene expression is critical for the accurate measurement of...

journal_title：Inflammatory bowel diseases

authors： Bamias G,Goukos D,Laoudi E,Balla IG,Siakavellas SI,Daikos GL,Ladas SD

更新日期：2013-12-01 00:00:00

abstract：:Chronic inflammatory bowel disease (IBD) presents as two major clinical forms, Crohn's disease (CD) and ulcerative colitis (UC). Genetic epidemiological studies and animal models suggest that inherited factors play significant roles in the susceptibility to both forms of IBD. From four genome-wide scans, putative susc...

journal_title：Inflammatory bowel diseases

authors： Ma Y,Ohmen JD,Li Z,Bentley LG,McElree C,Pressman S,Targan SR,Fischel-Ghodsian N,Rotter JI,Yang H

更新日期：1999-11-01 00:00:00

abstract：BACKGROUND:Inflammatory bowel disease (IBD)-associated dysbiosis is characterized by a loss of Faecalibacterium prausnitzii, whose supernatant exerts an anti-inflammatory effect. However, the anti-inflammatory substances in F. prausnitzii supernatant and the mechanism in ameliorating colitis in IBD have not yet been fu...

journal_title：Inflammatory bowel diseases

authors： Zhou L,Zhang M,Wang Y,Dorfman RG,Liu H,Yu T,Chen X,Tang D,Xu L,Yin Y,Pan Y,Zhou Q,Zhou Y,Yu C

更新日期：2018-08-16 00:00:00

abstract：BACKGROUND:Up to 20% of patients with ulcerative colitis (UC) become steroid-dependent during their course. Thiopurines are recommended in steroid-dependent UC, but their efficacy is debated. Data exploring the use of infliximab in these patients are scarce. Aims of this study were to evaluate the effectiveness of infl...

journal_title：Inflammatory bowel diseases

authors： Armuzzi A,Pugliese D,Danese S,Rizzo G,Felice C,Marzo M,Andrisani G,Fiorino G,Sociale O,Papa A,De Vitis I,Rapaccini GL,Guidi L

更新日期：2013-04-01 00:00:00

abstract：:Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured regularly show that nephrotoxicity is exceptional (mean rate of only 0.26% per patient-year). ...

journal_title：Inflammatory bowel diseases

authors： Gisbert JP,González-Lama Y,Maté J

更新日期：2007-05-01 00:00:00

abstract：:Inflammatory bowel disease (IBD) is a chronic intestinal disorder comprising 2 distinct but often overlapping diseases: Crohn's disease and ulcerative colitis. Although much research to identify the etiology of IBD has focused on genetic constitution, infectious causes, and immune dysregulation, its exact cause and pa...

journal_title：Inflammatory bowel diseases

authors： Ibrahim CB,Aroniadis OC,Brandt LJ

更新日期：2010-04-01 00:00:00

abstract：:Lymphocyte migration is at the heart of chronic inflammatory ailments, including inflammatory bowel disease (IBD). Whereas naïve lymphocytes migrate to all secondary lymphoid organs, they are mostly excluded from nonlymphoid peripheral tissues. Upon activation, lymphocytes change their pattern of adhesion receptors an...

journal_title：Inflammatory bowel diseases

authors： Mora JR

更新日期：2008-02-01 00:00:00

abstract：:Corticosteroids are considered a drug of choice for the treatment of patients with moderately to severely active Crohn's disease (CD), an inflammatory bowel disease characterized by chronic recurrent flares of disease activity. However, among patients receiving corticosteroid therapy for induction of remission, 20% ha...

journal_title：Inflammatory bowel diseases

authors： Lichtenstein GR

更新日期：2001-05-01 00:00:00

abstract：BACKGROUND:Mesenchymal stem cells (MSCs) have demonstrated significant potentials for the treatment of inflammatory bowel disease. Clinical feasible methods to individually document the MSC recruitment to intestinal mucosa is lacking. Here, we proposed that endomicroscopy could noninvasively track MSCs in vivo at cellu...

journal_title：Inflammatory bowel diseases

authors： Li M,Zhang YX,Zhang Z,Zhou XY,Zuo XL,Cong Y,Li YQ

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustai...

journal_title：Inflammatory bowel diseases

authors： Lee JH,Cheon JH,Jeon SW,Ye BD,Yang SK,Kim YH,Lee KM,Im JP,Kim JS,Lee CK,Kim HJ,Kim EY,Kim KO,Jang BI,Kim WH

更新日期：2013-08-01 00:00:00

abstract：:Restorative proctocolectomy with ileal-pouch anal anastomosis (RPC) is the operation of choice for ulcerative colitis (UC) patients requiring surgery. It is also used for patients with familial adenomatous polyposis (FAP). Pouchitis accounts for 10% of pouch failures. It is an idiopathic inflammatory condition that ma...

journal_title：Inflammatory bowel diseases

authors： Landy J,Al-Hassi HO,McLaughlin SD,Knight SC,Ciclitira PJ,Nicholls RJ,Clark SK,Hart AL

更新日期：2012-06-01 00:00:00

abstract：BACKGROUND:Drug concentration monitoring may be useful to guide therapeutic adjustments for anti-tumor necrosis factor agents in Crohn's disease. The relationship between serum adalimumab concentrations and clinical outcomes was assessed using data from CLinical Assessment of Adalimumab Safety and Efficacy Studied as I...

journal_title：Inflammatory bowel diseases

authors： Chiu YL,Rubin DT,Vermeire S,Louis E,Robinson AM,Lomax KG,Pollack PF,Paulson SK

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:The clinical utility of cellular therapies is being investigated in a broad range of therapeutic areas. This phase 1 study represents the first exploration of PDA001, a preparation of cells cultured from human placental tissue, in subjects with Crohn's disease. METHODS:Twelve subjects with active, moderate-...

journal_title：Inflammatory bowel diseases

authors： Mayer L,Pandak WM,Melmed GY,Hanauer SB,Johnson K,Payne D,Faleck H,Hariri RJ,Fischkoff SA

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:The early molecular changes preceding the onset of mucosal inflammation in colitis and their temporal relationship with gut permeability remain poorly defined. This study investigated functional and transcriptomic changes in mdr1a(-/-) mice lacking the intestinal transporter P-glycoprotein, which develop col...

journal_title：Inflammatory bowel diseases

authors： Collett A,Higgs NB,Gironella M,Zeef LA,Hayes A,Salmo E,Haboubi N,Iovanna JL,Carlson GL,Warhurst G

更新日期：2008-05-01 00:00:00

abstract：BACKGROUND:Inflammation-associated lymphangiogenesis (IAL) is frequently observed in inflammatory bowel diseases. IAL is believed to limit inflammation by enhancing fluid and immune cell clearance. Although monocytes/macrophages (MΦ) are known to contribute to intestinal pathology in inflammatory bowel disease, their r...

journal_title：Inflammatory bowel diseases

authors： Becker F,Kurmaeva E,Gavins FN,Stevenson EV,Navratil AR,Jin L,Tsunoda I,Orr AW,Alexander JS,Ostanin DV

更新日期：2016-06-01 00:00:00

abstract：BACKGROUND:Patients with inflammatory bowel disease (IBD) are more susceptible to mental health problems than the general population; however, temporal trends in psychiatric diagnoses' incidence or prevalence in the United States are lacking. We sought to identify these trends among patients with IBD using national Vet...

journal_title：Inflammatory bowel diseases

authors： Thakur ER,Sansgiry S,Kramer JR,Waljee AK,Gaidos JK,Feagins LA,Govani SM,Dindo L,El-Serag HB,Hou JK

更新日期：2020-08-20 00:00:00

abstract：BACKGROUND:Inflammatory bowel disease (IBD) is a multifactorial disorder, with the innate and adaptive immune cells contributing to disease initiation and progression. However, the intricate cross-talk between immune cell lineages remains incompletely understood. The role of CD8+ T cells in IBD pathogenesis has been un...

journal_title：Inflammatory bowel diseases

authors： Jamwal DR,Marati RV,Harrison CA,Midura-Kiela MT,Figliuolo Paz VR,Besselsen DG,Ghishan FK,Kiela PR

更新日期：2020-01-06 00:00:00

abstract：OBJECTIVES:There is some uncertainty regarding how to best dose and therapeutically monitor 6-mercaptopurine or azathioprine in patients with inflammatory bowel disease. The purpose of this study was to assess the relation between clinical response, 6-mercaptopurine metabolite levels, relative leukopenia, and drug dose...

journal_title：Inflammatory bowel diseases

authors： Achkar JP,Stevens T,Easley K,Brzezinski A,Seidner D,Lashner B

更新日期：2004-07-01 00:00:00

abstract：:: We sought to characterize the incidence, nature, and course of liver disease in children with inflammatory bowel disease (IBD). Chart review identified 555 subjects (318 Crohn's disease [CD], 237 ulcerative colitis [UC]). An alanine aminotransferase measurement of ≥80 U/L was used to identify the presence of a hepat...

journal_title：Inflammatory bowel diseases

authors： Hyams J,Markowitz J,Treem W,Davis P,Grancher K,Daum F

更新日期：1995-04-01 00:00:00

abstract：BACKGROUND:The role of antiviral therapy in patients with ulcerative colitis (UC) with cytomegalovirus (CMV) remains unclear. We therefore performed a systematic review and meta-analysis to assess the association between antiviral therapy and the risk of colectomy. METHODS:Multiple electronic databases were searched s...

journal_title：Inflammatory bowel diseases

authors： Shukla T,Singh S,Loftus EV Jr,Bruining DH,McCurdy JD

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Inflammatory bowel diseases (IBDs) are chronic illnesses that require frequent and regular healthcare contact. Regular maintenance care may reduce complications or the need for hospitalization. Availability of physicians may be an important determinant of IBD hospitalizations. METHODS:Using 2008 inpatient d...

journal_title：Inflammatory bowel diseases

authors： Ananthakrishnan AN,McGinley EL,Binion DG,Saeian K

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Although many genetic variants are identified in association with Crohn's disease (CD), CARD15, IL23R, and ATG16L1 association with CD have been firmly confirmed in Caucasians of European ancestry. The prevalence of CD is rapidly rising in Brazil, where European ancestry is firmly admixed with natives and Af...

journal_title：Inflammatory bowel diseases

authors： Baptista ML,Amarante H,Picheth G,Sdepanian VL,Peterson N,Babasukumar U,Lima HC,Kugathasan S

更新日期：2008-05-01 00:00:00

abstract：BACKGROUND:CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone....

journal_title：Inflammatory bowel diseases

authors： Reinisch W,Panaccione R,Bossuyt P,Baert F,Armuzzi A,Hébuterne X,Travis S,Danese S,Sandborn WJ,Schreiber S,Berg S,Zhou Q,Kligys K,Neimark E,Suleiman AA,D'Haens G,Colombel JF

更新日期：2020-09-18 00:00:00

abstract：BACKGROUND:Disappearance of macroscopic mucosal inflammation predicts long-term outcome in Crohn's disease (CD). It can be assessed by ileocolonoscopy, which is, however, an invasive and expensive procedure. Disease activity indices do not correlate well with endoscopic activity and noninvasive markers have a low sensi...

journal_title：Inflammatory bowel diseases

authors： Bodelier AG,Smolinska A,Baranska A,Dallinga JW,Mujagic Z,Vanhees K,van den Heuvel T,Masclee AA,Jonkers D,Pierik MJ,van Schooten FJ

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:Obesity is associated with systemic and intestine-specific inflammation and alterations in gut microbiota, which in turn impact mucosal immunity. Nonetheless, a specific role of obesity and its interaction with genetics in the progression of Crohn's disease (CD) is unclear. METHODS:We conducted a cross-sect...

journal_title：Inflammatory bowel diseases

authors： Pringle PL,Stewart KO,Peloquin JM,Sturgeon HC,Nguyen D,Sauk J,Garber JJ,Yajnik V,Ananthakrishnan AN,Chan AT,Xavier RJ,Khalili H

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:Ulcerative colitis (UC), a chronic, relapsing, and remitting inflammatory bowel disease, requires long-term treatment to maintain remission. In this study, the long-term safety and tolerability of mesalamine granules (MG) therapy was evaluated in the maintenance of UC remission. Previous prospective studies ...

journal_title：Inflammatory bowel diseases

authors： Lichtenstein GR,Barrett AC,Bortey E,Paterson C,Forbes WP

更新日期：2014-08-01 00:00:00

abstract：BACKGROUND:Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day. The primary objective of this study was to show the noninferiority of once-daily administration of a novel 1 g mesalamine suppository versus thrice-daily administration...

journal_title：Inflammatory bowel diseases

authors： Andus T,Kocjan A,Müser M,Baranovsky A,Mikhailova TL,Zvyagintseva TD,Dorofeyev AE,Lozynskyy YS,Cascorbi I,Stolte M,Vieth M,Dilger K,Mohrbacher R,Greinwald R,International Salofalk Suppository OD Study Group.

更新日期：2010-11-01 00:00:00